Mizuho Starts Biotech Stocks: (AMGN) (BIIB) (CELG) (ONXX) (RDEA) at Buy, (SVNT) at Neutral

Article Stock Quotes (6) Comments (0)

In the Biotech sector Wednesday evening, an analyst at Mizuho Securities initiated coverage on a number of stocks:

• Amgen (Nasdaq: AMGN) with a Buy rating and a $64 price target
  
• Biogen (Nasdaq: BIIB) with a Buy rating and a $87 price target
  
• Celgene (Nasdaq: CELG) with a Buy rating and a $68 price target
  
• Onyx Pharma (Nasdaq: ONXX) with a Buy rating and a $43 price target
  
• Ardea Biosciences (Nasdaq: RDEA) with a Buy rating and a $41 price target
  
• Savient Pharma (Nasdaq: SVNT) with a Neutral rating and a $12 price target

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Topeka Capital Sees Attractive Entry in Ducommun (DCO); Starts at Buy

Create E-mail Alert Related Categories

New Coverage

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?